J. Goldman & CO LP Catalyst Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

$3.21 Billion
Q3 2024

A detailed history of J. Goldman & CO LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 13,500 shares of CPRX stock, worth $291,870. This represents 0.01% of its overall portfolio holdings.

Number of Shares

13,500

Previous 20,250 33.33%

Holding current value

$291,870

Previous $313,000 14.38%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$15.19 - $21.35 $102,532 - $144,112	-6,750 Reduced 33.33%	13,500 $268,000
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $90,164 - $103,922	-6,142 Reduced 23.27%	20,250 $313,000
Q1 2024 May 15, 2024	SELL	$13.18 - $17.11 $4,599 - $5,971	-349 Reduced 1.31%	26,392 $420,000
Q4 2023 Feb 14, 2024	BUY	$11.78 - $17.29 $155,978 - $228,936	13,241 Added 98.08%	26,741 $449,000
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $6 Million - $7.71 Million	-513,202 Reduced 97.44%	13,500 $157,000
Q2 2023 Aug 14, 2023	BUY	$11.5 - $18.08 $4.79 Million - $7.53 Million	416,214 Added 376.71%	526,702 $7.08 Million
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $1.58 Million - $2.33 Million	110,488 New	110,488 $1.83 Million
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $320,614 - $548,391	-107,951 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$3.48 - $5.05 $1.21 Million - $1.75 Million	-346,822 Reduced 76.26%	107,951 $499,000
Q1 2020 May 15, 2020	BUY	$2.61 - $5.21 $1.19 Million - $2.37 Million	454,773 New	454,773 $1.75 Million

Others Institutions Holding CPRX

# of Institutions

326

Shares Held

94M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.22B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account